Risk Factors for Emergency Room and Hospital Care Among Patients With Solid Tumors on Immune Checkpoint Inhibitor Therapy.
暂无分享,去创建一个
A. Leiter | W. Oh | M. Galsky | M. Yin | S. Clinton | E. Gallagher | A. Mortazavi | C. Tsao | Q. Qin | P. Monk | E. Folefac | X. Zhong | V. Patel | Yuanquan Yang | A. Parikh | George Mellgard | Bo Wang | Parissa Alerasool | P. Garcia | G. Mellgard
[1] P. Kantoff,et al. Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry , 2020, Prostate Cancer and Prostatic Diseases.
[2] Characteristics of hospitalizations among patients receiving immune checkpoint inhibitors at a community teaching hospital , 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[3] C. Friese,et al. Racial and Ethnic Disparities in Emergency Department Care and Health Outcomes Among Children in the United States , 2019, Front. Pediatr..
[4] L. Newby,et al. Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review. , 2019, Journal of the American College of Cardiology.
[5] G. Coukos,et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance , 2019, Nature Reviews Clinical Oncology.
[6] M. Paasche-Orlow,et al. Association of Race/Ethnicity With Emergency Department Destination of Emergency Medical Services Transport , 2019, JAMA network open.
[7] T. Owonikoko,et al. Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy , 2019, BMC Cancer.
[8] R. Mehra,et al. Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes. , 2019, Journal of oncology practice.
[9] Xin Wang,et al. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. , 2019, JAMA oncology.
[10] E. B. Butler,et al. Racial and Socioeconomic Disparities in the Delivery of Immunotherapy for Metastatic Melanoma in the United States , 2019, Journal of immunotherapy.
[11] S. Sridhar,et al. Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients. , 2019, Clinical lung cancer.
[12] D. Francis,et al. Mortality From Ischemic Heart Disease , 2019, Circulation. Cardiovascular quality and outcomes.
[13] T. Owonikoko,et al. Enrollment of Racial Minorities in Clinical Trials: Old Problem Assumes New Urgency in the Age of Immunotherapy. , 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[14] Vinay Prasad,et al. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs , 2019, JAMA network open.
[15] Charles R. Thomas,et al. Analysis of Diagnoses, Symptoms, Medications, and Admissions Among Patients With Cancer Presenting to Emergency Departments , 2019, JAMA network open.
[16] Joe Y. Chang,et al. Racial and Insurance-related Disparities in Delivery of Immunotherapy-type Compounds in the United States , 2019, Journal of immunotherapy.
[17] E. Atenafu,et al. Hospitalisations and emergency department visits in cancer patients receiving systemic therapy: Systematic review and meta‐analysis , 2018, European journal of cancer care.
[18] A. Abernethy,et al. Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials , 2018, JAMA oncology.
[19] Muhammad Masab,et al. Clinical outcomes of African American patients with advanced or metastatic non-small cell lung cancer on Nivolumab in a single community-based cancer center , 2018, Medical Oncology.
[20] H. Tiwari,et al. Adoption rates of immune checkpoint inhibitors in real world oncology practice. , 2018 .
[21] B. Carr,et al. Trends in the Contribution of Emergency Departments to the Provision of Hospital-Associated Health Care in the USA , 2018, International journal of health services : planning, administration, evaluation.
[22] J. Brahmer,et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary. , 2018, Journal of oncology practice.
[23] M. Suarez‐Almazor,et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] J. Metsemakers,et al. Cardiovascular disease patients have increased risk for comorbidity: A cross-sectional study in the Netherlands , 2017, The European journal of general practice.
[25] N. Chalmers. Racial Disparities in Emergency Department Utilization for Dental/Oral Health-Related Conditions in Maryland , 2017, Front. Public Health.
[26] Susan Halabi,et al. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Coral L. Atoria,et al. ReCAP: Hospitalizations in Older Adults With Advanced Cancer: The Role of Chemotherapy. , 2016, Journal of oncology practice.
[28] Alejandro Lucia,et al. Epidemiology of coronary heart disease and acute coronary syndrome. , 2016, Annals of translational medicine.
[29] J. Wolchok,et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] J. Wolchok,et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[31] E. Atenafu,et al. Frequency and predictors of hospitalization during chemotherapy: a systematic review. , 2015 .
[32] T. Bethea,et al. Health Disparities and Cancer: Racial Disparities in Cancer Mortality in the United States, 2000–2010 , 2015, Front. Public Health.
[33] N. Cheedella,et al. Liver Metastases in Prostate Carcinoma Represent a Relatively Aggressive Subtype Refractory to Hormonal Therapy and Short-Duration Response to Docetaxel Monotherapy , 2015, World journal of oncology.
[34] N. Esnaola,et al. Racial differences and disparities in cancer care and outcomes: where's the rub? , 2012, Surgical oncology clinics of North America.
[35] S. Hendren,et al. Eliminating Disparities in Cancer Screening and Follow-up of Abnormal Results: What Will It Take? , 2011, Journal of health care for the poor and underserved.
[36] Mary A. Gerend,et al. Social Determinants of Black-White Disparities in Breast Cancer Mortality: A Review , 2008, Cancer Epidemiology Biomarkers & Prevention.
[37] C. Gross,et al. Racial disparities in cancer therapy , 2008, Cancer.
[38] Roger B. Davis,et al. Racial and ethnic disparities in cancer screening the importance of foreign birth as a barrier to care , 2003, Journal of General Internal Medicine.
[39] A. Garg,et al. Chronic kidney disease and mortality risk: a systematic review. , 2006, Journal of the American Society of Nephrology : JASN.
[40] Thomas E Novotny,et al. US Department of Health and Human Services: a need for global health leadership in preparedness and health diplomacy. , 2006, American journal of public health.